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Dear Sir,
Fluid therapy has always been considered as a 
cornerstone of surgical and critically ill patients. 
However, uncertainty about the appropriate choice of 
fluid for volume replacement persists. 
Crystalloids and colloids, the two major categories 
of fluid therapy used, have been the subject of an 
ongoing debate as to which of the two is the safer and 
more effective resuscitative fluid. 
Colloids have been used as volume expanders for 
acute fluid resuscitation in shocked patients. This is 
because colloids are thought to have longer intravascular 
persistence and therefore a longer volume replacement 
effect resulting in lower total volume needed and less 
extravascular oedema. However, synthetic colloids 
may negatively affect coagulation and are potentially 
nephrotoxic. "Modern" hydroxyethyl starches (HES) 
were considered relatively safe and were widely 
used, especially in Europe, until recently. However, 
HES solutions have been recently shown to increase 
both mortality and the risk for renal replacement 
therapy among some classes of critically ill patients. 
Accordingly, their indications have been significantly 
restricted. 
On 14 June 2013, following a review of the 
available evidence, the European Medicines Agency's 
Pharmacovigilance Risk Assessment Committee 
(PRAC) concluded that the benefits of infusion 
solutions containing hydroxyethyl-starch (HES) no 
longer outweigh their risks and therefore recommended 
that the marketing authorisations for these medicines 
be suspended1. Consequently, the Italian National Drug 
Agency introduced a measure for the withdrawal of 
all remaining stocks of HES solutions at clinicians' 
disposal2. Accordingly, in its recommendations for the 
application of a Patient Blood Management (PBM) 
programme in elective major orthopaedic surgery in 
adults, the experts from the Italian National Blood 
Centre outlined that HES solutions should not be used 
to correct acute hypovolaemia in bleeding patients 
because of the increased risk of mortality and renal 
failure3. However, in a following document4, the PRAC 
modified its recommendation. In fact, the Committee 
confirmed that HES solutions must no longer be used 
to treat patients with sepsis or burn injuries or critically 
ill patients because of an increased risk of kidney injury 
and mortality but concluded that HES solutions may 
continue to be used in patients to treat hypovolaemia 
caused by sudden blood loss where treatment with 
alternative infusions solutions (namely "crystalloids") 
alone are not considered to be sufficient. Moreover, in 
order to minimise potential risks in these patients, the 
PRAC recommended that HES solutions should not 
be used for more than 24 hours and patients' kidney 
function should be monitored after HES administration. 
Consequently, the Italian National Drug Agency made 
HES solutions available for clinical use exclusively in 
hypovolaemic, haemorrhagic patients5.
Therefore, the Authors of the Italian national 
guidelines on PBM wish to hereby acknowledge 
what the PRAC and the Italian National Drug Agency 
outlined in their latest statements that partially modifies 
the recommendation included in the previously 
published guidelines where they refer to HES solutions3. 
Accordingly, the following recommendation: "it is 
recommended that hydroxyethyl starch solutions are 
not used to correct acute hypovolaemia in bleeding 
patients because of the increased risk of mortality and 
renal failure [1B]" is now to be considered modified 
as follows: "hydroxyethyl starch solutions may be 
used in patients with hypovolaemia caused by sudden 
blood loss where treatment with crystalloids alone are 
not considered to be sufficient" [1B]. 
Hopefully, in the next years new data about the 
safety and efficacy of HES solutions will be provided 
by currently ongoing studies possibly putting an end 
to a, so far, never ending controversy.
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